Receptor BioLogix Acquires Late-Stage Cancer Vaccine
Posted on: Tuesday, 1 August 2006, 21:00 CDT
Cancer biopharmaceuticals developer Receptor BioLogix has acquired the late-stage cancer vaccine Insegia, and related assets, from Aphton in a chapter 11 bankruptcy sale.
Insegia, also known as G17DT, is a therapeutic cancer vaccine that has been extensively studied for its effects on cancers of gastrointestinal (GI) origin. The immunotherapeutic stimulates the body to produce antibodies that neutralize the peptide hormone, gastrin. Normally involved in the stimulation of gastric acid secretion for digestion, gastrin is a potent growth factor for GI malignancies, including stomach cancer and pancreatic cancer - two of the most deadly forms of cancer, neither of which have satisfactory treatments.
Two phase III clinical trials of Insegia have been completed in patients with advanced pancreatic cancer, and multiple phase II trials have been undertaken in patients with stomach cancer, which have shown promising results.
According to Dr Michael Shepard, Receptor BioLogix' chief scientific officer, the company is well positioned to further develop Insegia. "Insegia will become the most advanced product in our growing portfolio of growth factor receptor antagonists to treat cancer and other diseases," he said. "It fits very well with our product development programs, especially because a principal mechanism of gastrin tumor promotion is likely mediated through a member of the EGF receptor family, an area of focus for our company."
Financial details were not disclosed but the transaction is expected to close within 30 days, subject to certain conditions.
Source: Datamonitor
Related Articles
- Breast Cancer Hormone Receptor Status And Risk Of A Second Primary Tumor
- PET Scan Can Non Invasively Measure Early Assessment Of Treatment Of Breast Cancer
- Cell Receptor on Track for Painless Bladder Cancer Test
- Receptor BioLogix Acquires Late-Stage Cancer Drug From Aphton Corp.
- Aphton Announces Mutual Agreement to Dissolve Co-Promotion and Licensing Agreement Related to Anti-Cancer Product Insegia(TM) With Sanofi Pasteur
- Aphton Announces Results From Phase I Clinical Trial With Lewis Y Antibody IGN311 for Treatment of Epithelial Cancers
- Aphton Corporation Reports Data From Clinical Trial of Insegia in Combination With Chemotherapy in Pancreatic Cancer
- Association of Frequency and Duration of Aspirin Use and Hormone Receptor Status With Breast Cancer Risk
- Phase 3 Trial of Insegia in Pancreatic Cancer Does Not Meet Primary Endpoint; Survival Advantage Seen in Patients Who Achieve Antibody Response
- Aphton Corporation Announces Conference Call and Webcast to Discuss Phase 3 Clinical Results of Insegia
 |
 |
User Comments (0)
RSS Feeds